NCT00644956View on ClinicalTrials.gov

A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

November 30, 2003

Conditions

Erectile Dysfunction

Interventions

DRUG

tadalafil

tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)

DRUG

sildenafil

sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)

Trial Locations (2)

0277

Pfizer Investigational Site, Oslo

LS9 7TF

Pfizer Investigational Site, Leeds

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00644956 - A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil | Biotech Hunter | Biotech Hunter